Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Critical Therapeutics starts Phase I trial of zileuton
Twelve subjects will be randomly assigned to one of two groups of R(+) isomer zileuton (100mg or 300mg). The trial is designed to confirm that the R(+) isomer
Twelve subjects will be randomly assigned to one of two groups of R(+) isomer zileuton (100mg or 300mg). The trial is designed to confirm that the R(+) isomer
This grant will support further scientific development of NOV-002, in pivotal Phase III trial for non-small cell lung cancer under a special protocol assessment and fast track. Christopher
The study will evaluate three different doses of PYY3-36 nasal spray compared to placebo and sibutramine (Meridia), a commercially available oral weight loss drug. Patients in the active
Under the agreement, PerkinElmer will commence a cash tender offer to purchase all of the outstanding shares of ViaCell for $7.25 per share, for an aggregate purchase price
The companies intend to deploy these systems in support of drug discovery and clinical programs. Under the terms of the agreement, OSI will pay Aveo a total upfront
Mylan says it will benefit from substantial operational efficiencies and economies of scale from increased sales volumes and its vertically and horizontally integrated platform. The deal makes Mylan
Enjuvia is claimed to be the first and only plant-derived oral estrogen approved by FDA for the treatment of these specific symptoms associated with vaginal atrophy. James Simon,
The biologics license application (BLA) submission is based on data from the company’s pivotal Phase III acute trial which met its protocol-defined, pre-specified primary endpoint with statistical significance
The collaboration between Isis and Ortho-McNeil (OMI), includes the licensing of two second-generation antisense drugs, ISIS 325568 and ISIS 377131. ISIS 325568 was designed to selectively inhibit the
All current employees at the Rochester manufacturing facility have become JHP employees. Peter Jenkins, CEO of JHP, said: “JHP is deeply appreciative of King’s support in the enormous